Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Cited by 133 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cell, 2014, 159(5):1110-25

PubMed: 25416949 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):185

PubMed: 31053152 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )
Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1666-1676

PubMed: 30954557 ( click the link to review the publication )

Biomolecules, 2019, 9(5)

PubMed: 31083537 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(2)

PubMed: 30455231 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Mol Carcinog, 2019, 58(2):234-246

PubMed: 30303565 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

Childs Nerv Syst, 2019, 35(5):823-831

PubMed: 30815722 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Cancer Lett, 2018, 417:152-160

PubMed: 29306016 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1705-1716

PubMed: 29748211 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(2):201-212

PubMed: 29260509 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Arch Toxicol, 2017, 91(1):365-391

PubMed: 27015953 ( click the link to review the publication )
Arch Toxicol, 2017, 91(2):839-864

PubMed: 27188386 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Int J Nanomedicine, 2017, 12:1385-1399

PubMed: 28260886 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Exp Cell Res, 2017, 350(1):218-225

PubMed: 27914787 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169485

PubMed: 28052119 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1575-1583

PubMed: 29296798 ( click the link to review the publication )

Genom Data, 2017, 12:14-16

PubMed: 28239551 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:127-148

PubMed: 27761818 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

Retrovirology, 2016, 13(1):36

PubMed: 27206407 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )
Am J Transl Res, 2016, 8(9):3893-3902

PubMed: 27725868 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )

Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Biomaterials, 2015, 73:110-9

PubMed: 26406451 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Arch Toxicol, 2015, 89(9):1599-618

PubMed: 26272509 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

Mol Pharm, 2015, 12(7):2469-76

PubMed: 26030093 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

Exp Hematol, 2015, 43(6):448-61

PubMed: 25704054 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )

Br J Cancer, 2014, 111(2):281-91

PubMed: 24946002 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )
Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

Mol Carcinog, 2014, 53(9):722-35

PubMed: 23475695 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )

PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1325-34

PubMed: 23515752 ( click the link to review the publication )

PLoS One, 2013, 8(8):e74253

PubMed: 23991216 ( click the link to review the publication )

PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )
Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )

Genet Mol Res, 2013, 12(4):5405-13

PubMed: 24301913 ( click the link to review the publication )

The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

J Neurooncol, 2012, 110(3):335-48

PubMed: 23054560 ( click the link to review the publication )

Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Targets

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. ^[1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	M3n0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NESwSWcxNTFyIN88US=>	NFPXbG8xNTRiZB?=		MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MViyOlcxOjd6NB?=
HepG2	NG\ndZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDESFJQOC1zMDFOwG0>	M4HKNlAuPCCm		MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MV:yOlcxOjd6NB?=
HT29	NFzO[VRHfW6ldHnvckBCe3OjeR?=	NID5UIU2OMLibl2=	M3\BSlI1NTd{IHi=		NUe3VoJwcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB2ONMgbOKh	M2\NRVI3PzB{N{i0
HepG2	MX\GeY5kfGmxbjDBd5NigQ>?	MYW1NOKhdk1?	M{P4blI1NTd{IHi=		M1vnZYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhOjUEoHlCpC=>	MVOyOlcxOjd6NB?=
HCC827	NGDGSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmmzOU84NjVxMUCgcm0>	MmLiO\|LDqGh?	NWK0UHhkTE2VTx?=	NFTQU25mdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?=	MYeyOlY4PTR6NB?=
A549	NYTyN5ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWP1T45pOTBxMUWvNlAhdk1?	NUD4VnYxPzMEoHi=	NYG5fIo2TE2VTx?=	NVrPb2t3\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	NES3XoQzPjZ5NUS4OC=>
NCI-H460	NWq2XIFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjSZ2s3OTBxMkCvN\|Ahdk1?	M2X0dlczyqCq	MlzESG1UVw>?	MYLlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>?	MUeyOlY4PTR6NB?=
J89GFP	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXrOUVZzTE2VT9Mg	NUPIcHFyTUN3ME20PU45PSEEsTCxNk43PSCwTR?=	NEjRPY8zPjV4M{W2PC=>
THP89GFP	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWPmbVJGTE2VT9Mg	MXLFR\|UxRTF7LkO0JOKyKDZwNEOgcm0>	MoD6NlY2PjN3Nki=
SK-NEP-1	M4jxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnaboNmOC5yMfMAl\|ExNjBizszN	MnvzNlQhcA>?	NVzpSZFKTE2VT9Mg	MVjJR\|UxRTd4LkO0JI5O	NU\XXpVmOjZzN{[yNVk>
G401	MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnWUXMzOC5yMfMAl\|ExNjBizszN	NGHsRYMzPCCq	M1fzSWROW00EoB?=	MUDJR\|UxRTF2Mz6wNkBvVQ>?	NVfQT2ZoOjZzN{[yNVk>
SK-NEP-1	M1HmSWNmdGxiVnnhZoltcXS7IFHzd4F6	M{jUOlUxKG6P	M1rMRVHjiJN2IHS=	M3;0NWROW00EoB?=	NHPaRlNz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ?	M3HTWVI3OTd4MkG5
G401	M2XZ[2NmdGxiVnnhZoltcXS7IFHzd4F6	NFLBN3E2OCCwTR?=	MWGx5qCUPCCm	NFuzVVRFVVORwrC=	M4noRpJm\HWlZYOgZ4VtdCC\|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>?	M3ewc\|I3OTd4MkG5
SK-NEP-1	MWfBdI9xfG:\|aYOgRZN{[Xl?	NE\Ue3k2OC9zMECgcm0>	MnTJNlQhcA>?	MXzEUXNQyqB?	M3TGVIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NIjZeWUzPjF5NkKxPS=>
G401	M4jsXmFxd3C2b4Ppd{BCe3OjeR?=	M3njR\|UxNzFyMDDuUS=>	MmftNlQhcA>?	MofGSG1UV8Li	MVrpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M3;oeVI3OTd4MkG5
SK-NEP-1	NGr3Rm5HfW6ldHnvckBCe3OjeR?=	NF7LfmU2OC9zMECgcm0>	NH2xT4szPCCq	NH6wNXFFVVORwrC=	NUP0[nFme2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?=	NUnVOG9kOjZzN{[yNVk>
G401	NYDJ[FR3TnWwY4Tpc44hSXO\|YYm=	NF3OcmQ2OC9zMECgcm0>	M3jaTlI1KGh?	NUPlZ2czTE2VT9Mg	M{XzN5Npd3e\|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25?	NUO1TIloOjZzN{[yNVk>
SK-NEP-1	MnPGSpVv[3Srb36gRZN{[Xl?	MoSxOVAwOTByIH7N	MoPWNlQhcA>?	NUfHepZXTE2VT9Mg	NXv2cVRVcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB?	NFjVXHYzPjF5NkKxPS=>
G401	MljMSpVv[3Srb36gRZN{[Xl?	NXv1UpJ4PTBxMUCwJI5O	NFr0bYIzPCCq	MmewSG1UV8Li	MkWybY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA>	MXuyOlE4PjJzOR?=
RPMI 8226	MX;D[YxtKFO3co\peoFtKEG\|c3H5	NXO3PGRJOi92L{[gcm0>	NE\X[G41QOLCiXi=		NIm1dXpqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq	MV6yOlAxODJ7Mh?=
OPM2	M2GxbWNmdGxiU4Xyeol3[WxiQYPzZZk>	M37ZUFIwPC94IH7N	M{O5TlQ56oDLaB?=		NHyyWoRqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq	NUPxbJo4OjZyMECyPVI>
U266	MWXD[YxtKFO3co\peoFtKEG\|c3H5	MoDiNk81NzZibl2=	NX\p[XhsPDkkgJno		MV3pcoR2[2W\|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp	MYSyOlAxODJ7Mh?=
H929	NGjoVZBE\WyuIGP1dpZqfmGuIFHzd4F6	M3\XUVIwPC94IH7N	MorDOFjjiImq		NVKyRVl2cW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	NY\NSJIxOjZyMECyPVI>
RPMI 8226	Mn3PRZBweHSxc3nzJGF{e2G7	Mm\IOQKBkW6P	MUWyOE81QCCq		MlTubY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MoHFNlYxODB{OUK=
HCC827	NYPWUnRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHlNVAhdk1?	NILJXHE1QCCq	M2faSGROW09?	MnXJ[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB?	M{[xVVI2QTR2NkG3
NCI-H23	NGTaboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWCxNEBvVQ>?	M3fBVlQ5KGh?	NYnQdlJ6TE2VTx?=	NF3SZWtmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?=	NIfyem0zPTl2NE[xOy=>
AML3	NIm3W\|JHfW6ldHnvckBCe3OjeR?=	MYKwMVEh\|ryP	Mm[4NlTDqGh?		MWXpcoR2[2W\|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M1XH[VI2PjF{OUSx
ML-1	M2LpRWZ2dmO2aX;uJGF{e2G7	M3rC[VAuOSEQvF2=	MYiyOOKhcA>?		M1:yO4lv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NHvBNG0zPTZzMkm0NS=>
RPMI-8226vr10	MmfISpVv[3Srb36gRZN{[Xl?	M4HCelAuOSEQvF2=	NWTrOXI1OjUEoHi=		M4ewWYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MUeyOVYyOjl2MR?=
ML-1	M2LCUmZ2dmO2aX;uJGF{e2G7	MXSxJO69VQ>?	M4fx[VI1yqCq		NWnqS4lScW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ>	NGmwW5MzPTZzMkm0NS=>
RPMI-8226vr10	NXz3cXp[TnWwY4Tpc44hSXO\|YYm=	NGLRRlQyKM7:TR?=	NH7pe2EzPMLiaB?=		MWnpcoNz\WG\|ZYOgZ4F{eGG\|ZT2zJIFkfGm4aYT5JFIvPS2ob3zk	M{Xy[FI2PjF{OUSx
SK-N-BE (2)	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGnrZVAzPOLCiXi=		NEDwR2hKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2=	NFOwZmszPTNyOEmxOi=>
SK-N-BE (2), PAN MK	M4jmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnrHNlTjiImq		MXfJR\|UxRTFyND6w5qCKyrIkgJm3Mlghdk1?	NHXKeJUzPTNyOEmxOi=>
SK-N-BE (2), MK PAN	NUDwVmxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV:yOQKBkWh?		NGDqV\|NKSzVyPUO4Nk4x6oDLwsJihKk1Oy5{IH7N	MXqyOVMxQDlzNh?=
SK-N-AS	M2TJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1vGTFI16oDLaB?=		NG\pZXBKSzVyPUO3MlHjiIoEsfMAjVIvPCCwTR?=	NFiwToIzPTNyOEmxOi=>
SK-N-DZ	Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUiyOQKBkWh?		MmnsTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1?	MmrUNlU{ODh7MU[=
Caki-1	NGjMWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{WyPVExNzJ3L{WwJI5O	NV7RZZFuPDhiaB?=		MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ?	NH2zXlYzPTJ5OUG5NS=>
ACHN	NV3ZXJhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHNRpNSOTBxMkWvOVAhdk1?	MVG0PEBp		MYTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ?	NUfMUng4OjV{N{mxPVE>
769-P	NVXjNXpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;q[lExNzJ3L{WwJI5O	NGTNOoQ1QCCq		NI\QV2tqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	Mn;RNlUzPzlzOUG=
786-O	NGrtb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\SV\|IyOC9{NT:1NEBvVQ>?	MlfaOFghcA>?		M4T4WolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?=	NFHu[4UzPTJ5OUG5NS=>
Caki-1	MmrvRZBweHSxc3nzJGF{e2G7	MXG1NEBvVQ>?	NXW2[5dKPDhiaB?=		NG\nXVNqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	NXjrfXR6OjV{N{mxPVE>
ACHN	M2rMZ2Fxd3C2b4Ppd{BCe3OjeR?=	Ml3EOVAhdk1?	MXm0PEBp		MWfpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>?	MlftNlUzPzlzOUG=
769-P	NHvJeVFCeG:ydH;zbZMhSXO\|YYm=	NGqxVGI2OCCwTR?=	M2W4SVQ5KGh?		M363Nolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{	NGnkS\|czPTJ5OUG5NS=>
786-O	MoLtRZBweHSxc3nzJGF{e2G7	MoDBOVAhdk1?	Mon2OFghcA>?		MnGwbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ?	MXuyOVI4QTF7MR?=
Caki-1	M4n5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV60UVJWOjVxNUCgcm0>	MkDuOFghcA>?	NHnpN2JFVVOR	MlPibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?=	NXPYfHNWOjVzN{[zOVQ>
ACHN	M1PCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2joXlI2NzVyIH7N	MXm0PEBp	MVrEUXNQ	NInvPGtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni	NEHsWXAzPTF5NkO1OC=>
769-P	M1faXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHPNlUwPTBibl2=	NWnHNoZlPDhiaB?=	MWPEUXNQ	NHflZYVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni	M2fITlI2OTd4M{W0
Caki-1	NY[2foJVS2:ub375JGZwem2jdHnvckBCe3OjeR?=	NWq3c2pQPTBibl2=	NXn0dHVuPy1zNDDk	NI\jRm1FVVOR	M1LsTpN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh	NWX0flZkOjVzN{[zOVQ>
ACHN	M3e3NGNwdG:weTDGc5Ju[XSrb36gRZN{[Xl?	M{nSN\|UxKG6P	M33tflcuOTRiZB?=	NEC4UXRFVVOR	MmDMd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA>	MYmyOVE4PjN3NB?=
769-P	NV3kZpBsS2:ub375JGZwem2jdHnvckBCe3OjeR?=	NWj3VW1PPTBibl2=	M3jZOFcuOTRiZB?=	Mnv5SG1UVw>?	Mo\nd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA>	MYKyOVE4PjN3NB?=
Caki-1	NYPjVFF4SXCxcITvd4l{KEG\|c3H5	M2T5WlUxKG6P	MmTMOFghcA>?	NXHaS41XTE2VTx?=	NVXF[WNOcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	Mmf3NlUyPzZ\|NUS=
ACHN	MUfBdI9xfG:\|aYOgRZN{[Xl?	M1H4WVUxKG6P	M1ezflQ5KGh?	M{TLUGROW09?	NYXQdY9{cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MlTGNlUyPzZ\|NUS=
769-P	NHjtUoNCeG:ydH;zbZMhSXO\|YYm=	M3HhVVUxKG6P	M1fwWlQ5KGh?	Mme2SG1UVw>?	MVTpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NFrGfYozPTF5NkO1OC=>
MDA-MB-231	MnPmUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6	MnyxNVDDqG6P	MXOzxsBl	NFzRZY1FVVOR	MXXhcJRmenNiY3XscEBud3KyaH;sc4d6yqB?	Mo\rNlQ5OTB2OUe=
BT-549	M4G0fG1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>?	MVuxNOKhdk1?	MkXNN:Kh\A>?	NWS4Wll4TE2VTx?=	NWmwZox4[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg	MnLNNlQ5OTB2OUe=
MCF-7	M1\zUG1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>?	NWXYXYN{OTEEoH7N	MVqzxsBl	MmjZSG1UVw>?	NHv5T49idHSncoOgZ4VtdCCvb4LwbI9td2e7wrC=	MWOyOFgyODR7Nx?=
MCF-7	NWDL[49bTnWwY4Tpc44hSXO\|YYm=	MXW1MVUxKG6P	NFj1TZYzPCCq	NUjINFI3TE2VTx?=	NUXHTJlQemWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>?	M37Fe\|I1OzZ4NEC3
CTS	M2XjcWFxd3C2b4Ppd{BCe3OjeR?=	MnT5NQKBmzRyIH7NxsA>	MoizOFghcA>?		M1TTNYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MXOyOFI1PDR{OR?=
OCI-AML3	MULBdI9xfG:\|aYOgRZN{[Xl?	MkfINQKBmzRyIH7NxsA>	Ml\NOFghcA>?		MYTpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	Mm\4NlQzPDR2Mkm=
U937	MnrNRZBweHSxc3nzJGF{e2G7	NX;IfGlnOOLCk{SwJI5OyqB?	MUe0PEBp		M{PCSolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M3nXUFI1OjR2NEK5
PC3	M{nKZmFxd3C2b4Ppd{BCe3OjeR?=	M3P0WlAuOTByIH7N	MnPDNlQwPDhiaB?=		NIf6eWdqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NYWyR5NuOjRzNkOyN\|A>
PC3-AR	NIfKdXRCeG:ydH;zbZMhSXO\|YYm=	NUHvO2o3OC1zMECgcm0>	NIewVpMzPC92ODDo		M4ju[Ilv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NVXvVotMOjRzNkOyN\|A>
PC3	M{XmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLTNVRjOC1zMECgcm0>	MX2yOE81QCCq		NVraVGplcW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gd5VjTzFicH;weYxifGmxbh?=	NED3WVYzPDF4M{KzNC=>
PC3-AR	NFnUWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHJcHU5OC1zMECgcm0>	M3;KelI1NzR6IHi=		M2G2N4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG\|ZR?=	NU\5W3g4OjRzNkOyN\|A>
PC3	NU\2WoxRTnWwY4Tpc44hSXO\|YYm=	MXSwMVExOCCwTR?=	NG\oVJMzPCCq		NHTyeWF{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM\|IheHKxdHXpci=>	NEGyOGkzPDF4M{KzNC=>
PC3-AR	M3XL[WZ2dmO2aX;uJGF{e2G7	MoDKNE0yODBibl2=	MV6yOEBp		MVjzeZBxemW\|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?=	MYKyOFE3OzJ\|MB?=
OS-RC-2	M3f4bmNmdGxiVnnhZoltcXS7IFHzd4F6	MWGwMVExODBibl2=	M1XsRlI1NzR6L{eyJIg>	M4PVUGROW09?	MYjk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFq5blgzPDF2NEezOy=>
OS-RC-2	MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLXdogzPTBibl2=	NVjjemlKPDhiaB?=	NInv[4pFVVOR	MVLpcoR2[2W\|IFeyM20h[XK{ZYP0	M{G5V\|I1OTR2N{O3
OS-RC-2	NECxNWxCeG:ydH;zbZMhSXO\|YYm=	MYS1NEBvVQ>?	M2HYS\|Q5KGh?	MXLEUXNQ	NFLOW5BqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MX:yOFE1PDd\|Nx?=
SK-N-AS	NHeyfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVuw5qCUQDBibl2=	NYPyd3FtPDhiaB?=		MVHJR\|UxRTJ5LkSgcm0>	NVjiN2I3OjRyOUi3PVk>
SK-N-DZ	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XW[\|DjiJN6MDDuUS=>	Mn7tOFghcA>?		NYrFdVl1UUN3ME2yNU46KG6P	NVjzNXRzOjRyOUi3PVk>
SK-N-SH	NFjW[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlSxNQKBmzhyIH7N	NETCZVI1QCCq		NX[2N4RsUUN3ME23Nk4{KG6P	MoHINlQxQTh5OUm=
SK-N-BE	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\0NQKBmzhyIH7N	NUDXPItbPDhiaB?=		NFj1WHZKSzVyPUe1MlQhdk1?	NYrnZlF1OjRyOUi3PVk>
SK-N-AS	MoTYRZBweHSxc3nzJGF{e2G7	MViw5qCUQDBibl2=	M{LD[\|Q5KGh?		M2rnT5BwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	MkK1NlQxQTh5OUm=
SK-N-DZ	NVHh[29mSXCxcITvd4l{KEG\|c3H5	MlP5NQKBmzhyIH7N	NXTPVXE1PDhiaB?=		NEXjWWpxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44>	NYTCdWlMOjRyOUi3PVk>
SK-N-SH	MULBdI9xfG:\|aYOgRZN{[Xl?	M2\TWFDjiJN2MDDuUS=>	NI\yOW41QCCq		MkK2dI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	MlixNlQxQTh5OUm=
SK-N-BE	MVXBdI9xfG:\|aYOgRZN{[Xl?	M4LYUlDjiJN2MDDuUS=>	MlzJOFghcA>?		NIr5d2txd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44>	MXuyOFA6QDd7OR?=
SK-N-AS	MXjGeY5kfGmxbjDBd5NigQ>?	NXzKRXJ2OOLCk{iwJI5O	M2fu[\|Q5KGh?		NGC4S3JqdmS3Y3XzJIEh\G:\|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[UA{KGGwZDDQRXJR	M4H6VFI1ODl6N{m5
SK-N-DZ	NF[0TldHfW6ldHnvckBCe3OjeR?=	NWjkUXNZOOLCk{iwJI5O	MUG0PEBp		MlTHbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=>	MWOyOFA6QDd7OR?=
SK-N-SH	MV7GeY5kfGmxbjDBd5NigQ>?	MX[w5qCUPDBibl2=	NWnZSI1[PDhiaB?=		MkSxbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=>	MmDoNlQxQTh5OUm=
SK-N-BE	MUDGeY5kfGmxbjDBd5NigQ>?	MWGw5qCUPDBibl2=	NUXVVGVEPDhiaB?=		MUXpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG\|ZTCzJIFv\CCSQWLQ	NHTXXXczPDB7OEe5PS=>
HCC-LM3	NE\2SGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV6xMVExODBibl2=	MYeyOE81QC95MjDo	Ml7DSG1UVw>?	MlzWbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M1HRdVI1ODl\|OUW2
HepG2	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoC3NU0yODByIH7N	MoHaNlQwPDhxN{KgbC=>	NGDDeYpFVVOR	M4Dqe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M3LwOFI1ODl\|OUW2
SMMC-7721	NY\SV\|BbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUe4SHk2OS1zMECwJI5O	MXeyOE81QC95MjDo	MVfEUXNQ	NHiwUmtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MlvNNlQxQTN7NU[=
HCC-LM3	NWD6OJlkSXCxcITvd4l{KEG\|c3H5	Mnq3OVAhdk1?	Ml2xOFghcA>?	MmfiSG1UVw>?	M1y1[4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6	MWGyOFA6Ozl3Nh?=
HepG2	MX7BdI9xfG:\|aYOgRZN{[Xl?	M3XCXlUxKG6P	NFXBW4w1QCCq	MnvoSG1UVw>?	M3TnSolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6	MlPnNlQxQTN7NU[=
SMMC-7721	NFfkRVdCeG:ydH;zbZMhSXO\|YYm=	MVK1NEBvVQ>?	M4nIOlQ5KGh?	M4W2e2ROW09?	MV7pcoR2[2W\|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG\|ZYOgN{whQCCjbnSgPS=>	MViyOFA6Ozl3Nh?=
HCC-LM3	NHPxcFhHfW6ldHnvckBCe3OjeR?=	MX61NE8yODBibl2=	NV[4OGZZOjRiaB?=	M3XOfWROW09?	NFnjUmNl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR\|IHHu[EBxNUGtdNMg	MYSyOFA6Ozl3Nh?=
HepG2	NGG2[XBHfW6ldHnvckBCe3OjeR?=	MmjnOVAwOTByIH7N	MUWyOEBp	MWrEUXNQ	MlvZ[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?=	MYCyOFA6Ozl3Nh?=
SMMC-7721	MUDGeY5kfGmxbjDBd5NigQ>?	MXW1NE8yODBibl2=	MlHZNlQhcA>?	MmjpSG1UVw>?	NXr6OYpl\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=>	NFfvPWczPDB7M{m1Oi=>
HCC-LM3	M4nXdmZ2dmO2aX;uJGF{e2G7	M1jwVlUxNzFyMDDuUS=>	MYiyOEBp	NXOyNGZoTE2VTx?=	MVzkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v	MV:yOFA6Ozl3Nh?=
HepG2	NVOyeY5nTnWwY4Tpc44hSXO\|YYm=	MoXZOVAwOTByIH7N	NYTEeHlFOjRiaB?=	Mm[2SG1UVw>?	M3TBbIRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25?	MYOyOFA6Ozl3Nh?=
SMMC-7721	MmTlSpVv[3Srb36gRZN{[Xl?	NGXXRmI2OC9zMECgcm0>	NHn1[YQzPCCq	NFz6Z4xFVVOR	Mn7k[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>?	NFXMU\|QzPDB7M{m1Oi=>
FaDu	NFjHbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV[xNFDjiIWwTR?=	MXq4M\|ExNzF{IHi=		MYHkbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V?	M3HiflI1ODJ4NEiy
FaDu	M{jq[mZ2dmO2aX;uJGF{e2G7	Mkn4NVAx6oDHbl2=	Mom2Nk81NzhxMUKgbC=>		MnfSbY5lfWOnZDDwNlFY[WZzL1PpdFHDqGW6cILld5Nqd25?	MX6yOFAzPjR6Mh?=
PC-3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\sbHNCOC1zMDFOwG0>	M4rTSlI1NzR6L{eyJIg>		NWrsd2ZWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M3H4UFI{QTlzMkG2
LNCaP	Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{X1[VAuPSEQvF2=	MmfaNlQwPDhxN{KgbC=>		MmfjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NIfMR3AzOzl7MUKxOi=>
RWPE-1	NGPNSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoSxNE0zOCEQvF2=	MUiyOE81QC95MjDo		MnnQbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M4Dlb\|I{QTlzMkG2
Capan-1	MnzYSpVv[3Srb36gRZN{[Xl?	MYWyOU82OC9zMECgcm0>	MVi4M\|I1NzR6IHi=	MkHESG1UVw>?	NFXrfHZld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n	MV6yN\|kzOjh6Nh?=
L3.6pl	NF3TXY9HfW6ldHnvckBCe3OjeR?=	M3nl[\|I2NzVyL{GwNEBvVQ>?	MmHxPE8zPC92ODDo	MX7EUXNQ	NWmwO4gz\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=>	NE\4d20zOzl{Mki4Oi=>
CFPAC-1	Mn;VSpVv[3Srb36gRZN{[Xl?	MXqyOU82OC9zMECgcm0>	MVG4M\|I1NzR6IHi=	M1;PdWROW09?	M4TIWYRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW\|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne=	MnrxNlM6OjJ6OE[=
Capan-1	Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MViyOU82OC9zMECgcm0>	M2X3UVQ5KGh?	NEjiZphFVVOR	MXPy[YR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MX:yN\|kzOjh6Nh?=
L3.6pl	NHWxZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LubVI2NzVyL{GwNEBvVQ>?	MUi0PEBp	Mk\XSG1UVw>?	M1vyOJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NIrnbW8zOzl{Mki4Oi=>
CFPAC-1	M{m4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH64TYMzPS93MD:xNFAhdk1?	M2TMWlQ5KGh?	Mly4SG1UVw>?	NXHrRo1{emWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NVTwS2pEOjN7MkK4PFY>
Capan-1	M1rafWFxd3C2b4Ppd{BCe3OjeR?=	NYPOXoZGOjVxNUCvNVAxKG6P	M372UVQ5KGh?	MoTMSG1UVw>?	NInlRoNqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NFPDVokzOzl{Mki4Oi=>
L3.6pl	M{\Pc2Fxd3C2b4Ppd{BCe3OjeR?=	MmjHNlUwPTBxMUCwJI5O	NXjxOHhkPDhiaB?=	M2nWXWROW09?	M4LLNolv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NYHnfZhjOjN7MkK4PFY>
CFPAC-1	MXrBdI9xfG:\|aYOgRZN{[Xl?	Mk\wNlUwPTBxMUCwJI5O	M1XrSFQ5KGh?	MUTEUXNQ	MkjHbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MWGyN\|kzOjh6Nh?=
HN22	NFHYWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXWwMVIxKG6P	NU\wSXBZOjRxNEigbC=>	M125U2ROW09?	MlW0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=>	MVqyN\|g4PzJ\|NR?=
HSC4	NIDWRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWewMVIxKG6P	Mkf0NlQwPDhiaB?=	NFfGdFBFVVOR	M2rsVIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI>	NU\HWo5MOjN6N{eyN\|U>
HN22	M3vZTWFxd3C2b4Ppd{BCe3OjeR?=	NHLEUlYxNTJyIH7N	NGDOeXg1QCCq	NEDxU3NFVVOR	MVPpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MYeyN\|g4PzJ\|NR?=
HSC4	MV7BdI9xfG:\|aYOgRZN{[Xl?	MX2wMVIxKG6P	NYHnelR7PDhiaB?=	M4DITmROW09?	M2j2[Ylv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	M1K4N\|I{QDd5MkO1
HN22	NXz4eFVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV[wMVIxKG6P	MYC0PEBp	MXvEUXNQ	NUDxUnV1cW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh	MmnHNlM5Pzd{M{W=
HSC4	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXf6eGFQOC1{MDDuUS=>	MUG0PEBp	MlTxSG1UVw>?	NWezXnJ1cW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh	NWHzfpRTOjN6N{eyN\|U>
HN22	MUHGeY5kfGmxbjDBd5NigQ>?	M1nlVFAuOjBibl2=	M{fnVlQ5KGh?	M1;BbmROW09?	MWnzeZBxemW\|c3XzJHNxOSCneIDy[ZN{cW:wwrC=	NILwTWQzOzh5N{KzOS=>
HSC4	NXHNZWlyTnWwY4Tpc44hSXO\|YYm=	M1T1RVAuOjBibl2=	NUXOeXB{PDhiaB?=	MXzEUXNQ	NGfGR\|d{fXCycnXzd4V{KFOyMTDlfJBz\XO\|aX;uxsA>	MXWyN\|g4PzJ\|NR?=
Cal62	M{myOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{GwdGlEPTB;M{OgxtEhPCCwTR?=	M4jIRVI{QDJ2ME[0
Hth7	M2K0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1:1WWlEPTB;MUWgxtEhOiCwTR?=	NWjxcodROjN6MkSwOlQ>
Hth83	NUHXWldNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\RdGlEPTB;M{SgxtEhPSCwTR?=	NH;keGMzOzh{NEC2OC=>
C643	NUTlb\|d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTdzINMxJFExKG6P	M4nJeVI{QDJ2ME[0
SW1736	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTN3INMxJFghdk1?	NGPSO3kzOzh{NEC2OC=>
T241	NV;tZplyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHVTWM2OD14NTFCtUA4KG6P	MkHlNlM5OjRyNkS=
T351	M2nSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TFcGlEPTB;NUCgxtEhOTBibl2=	MVSyN\|gzPDB4NB?=
BHP2-7	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnP2TWM2OD1\|NzFCtUA3KG6P	M{D0clI{QDJ2ME[0
T238	NELHcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTFuNUCwJOKyKDJyMDDuUS=>	M2DMbFI{QDJ2ME[0
HCT8	NXeyO4JLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mo\YO\|IhcA>?	MUXEUXNQ	NXi5UFJyUUN3ME2xNk466oDLwsJihKkyNjlibl2=	NWfJdIVoOjN{OUmzPFg>
H630	M1LJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3jT[lczKGh?	MlLPSG1UVw>?	MV\JR\|UxRTF{LkVihKnDueLCiUOuNUBvVQ>?	M1vPdlI{Ojl7M{i4
cH630 5-FU-res	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHfwSnk4OiCq	MVPEUXNQ	NYDI[GE4UUN3ME2xOU426oDLwsJihKkyNjJibl2=	NXPLNpRuOjN{OUmzPFg>
HCT116	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkDoO\|IhcA>?	NVPG[IxMTE2VTx?=	M2fRb2lEPTB;MUCuO-KBkcLz4pEJNk4zKG6P	Mmi3NlMzQTl\|OEi=
HCT116 p53−/−	MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXXyUGIxPzJiaB?=	NYqxOZhpTE2VTx?=	NHLGUoZKSzVyPUiuOwKBkcLz4pEJNU44KG6P	Mke4NlMzQTl\|OEi=
dHCT116 p21−/−	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NY\oSFd2PzJiaB?=	NHi0NZRFVVOR	M4LNe2lEPTB;NT655qCKyrIkgJmxMlMhdk1?	NEj4bGQzOzJ7OUO4PC=>
HT29	MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWi3NkBp	NFLP[YhFVVOR	MYLJR\|UxRTF4LkRihKnDueLCiUKuN{BvVQ>?	M{n6TFI{Ojl7M{i4
LoVo	NWnCb2lyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2PMNlczKGh?	NW\xNY5DTE2VTx?=	NX;SbphOUUN3ME21MlHjiIoEsfMAjVAvPiCwTR?=	NH3IflgzOzJ7OUO4PC=>
RKO	NG[3N5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWWyVGRbPzJiaB?=	MlW3SG1UVw>?	M4m4UWlEPTB;Nz655qCKyrIkgJmyMlIhdk1?	Mo\vNlMzQTl\|OEi=
SW480	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYW3NkBp	MnnMSG1UVw>?	NXq0VpJNUUN3ME2xO{426oDLwsJihKkxNjhibl2=	NEPUVo8zOzJ7OUO4PC=>
eSW620	NUTo[nJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkL6O\|IhcA>?	NIjvdZBFVVOR	NUKz[nhDUUN3ME25MlHjiIoEsfMAjVIvOSCwTR?=	NW\xSXV7OjN{OUmzPFg>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

In vivo

In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. ^[2]

Protocol

Cell Research:^[1]	+ Expand Cell lines: MOLT-4 cell lines and Reh (pre-B cells) Concentrations: 50 nM Incubation Time: 48 hours Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 10⁴ cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (10⁷ cells) or A549 (5 × 10⁶ cells), H69 (2.5 × 10⁶ cells), BK-T (6.5 × 10⁶), H526 (10 × 10⁶), and RG1 (10 × 10⁶) cells Formulation: Dextrose 5% in water Dosages: 10 mg/kg, 20 mg/kg Administration: Administered via i.p. injection (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
Concentrations: 50 nM
Incubation Time: 48 hours
Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 10⁴ cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
(Only for Reference)

Animal Research:^[2]

+ Expand

Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (10⁷ cells) or A549 (5 × 10⁶ cells), H69 (2.5 × 10⁶ cells), BK-T (6.5 × 10⁶), H526 (10 × 10⁶), and RG1 (10 × 10⁶) cells
Formulation: Dextrose 5% in water
Dosages: 10 mg/kg, 20 mg/kg
Administration: Administered via i.p. injection
(Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+48% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Panobinostat (LBH589) SDF

Molecular Weight	349.43
Formula	C₂₁H₂₃N₃O₂
CAS No.	404950-80-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NVP-LBH589

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03632317	Withdrawn	Drug: Panobinostat\|Drug: Everolimus	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	October 2019	Phase 2
NCT03982134	Withdrawn	Drug: PDR001\|Drug: Panobinostat	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	September 2019	Phase 1
NCT03515915	Recruiting	--	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	April 23 2018	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to reconstitute the compound for in vivo mice study?
Answer:
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Vorinostat (SAHA, MK0683)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Panobinostat (LBH589)

Cited by 133 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Panobinostat (LBH589) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Panobinostat (LBH589)

Cited by 133 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Panobinostat (LBH589) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)